NCT02821000View on ClinicalTrials.gov

Safety and Efficacy Study of Pembrolizumab (MK-3475) in Chinese Participants With Locally Advanced or Metastatic Melanoma (MK-3475-151/KEYNOTE-151)

PHASE1CompletedINTERVENTIONAL
Enrollment

103

Participants

Timeline

Start Date

July 8, 2016

Primary Completion Date

December 27, 2017

Study Completion Date

November 30, 2022

Conditions
Melanoma
Interventions
BIOLOGICAL

Pembrolizumab

Intravenous infusion

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02821000 - Safety and Efficacy Study of Pembrolizumab (MK-3475) in Chinese Participants With Locally Advanced or Metastatic Melanoma (MK-3475-151/KEYNOTE-151) | Biotech Hunter | Biotech Hunter